Synthesis of (+)-Thiersindole C

Isidro S. Marcos; Miguel A. Escola; Rosalina F. Moro; Pilar Basabe; David Diez; Faustino Mollinedo; Julio G. Urones

doi:10.1055/s-2007-984893

LETTER

Synthesis of (+)-Thiersindole C

Isidro S. Marcos*^a, Miguel A. Escola^a, Rosalina F. Moro^a, Pilar Basabe^a, David Diez^a, Faustino Mollinedo^b,c, Julio G. Urones^a
^a Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad de Salamanca, Plaza de los Caídos 1-5, 37008 Salamanca, Spain
Fax: +34(923)294574; e-Mail: ismarcos@usal.es;
^b Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain
^c APOINTECH, Campus Miguel de Unamuno, 37007 Salamanca, Spain

Abstract

All articles of this category

Abstract

The indole diterpene alkaloid (+)-thiersindole C has been synthesised from ent-halimic acid. Firstly was elaborated the bicyclic system, secondly a Fischer indolization was used to obtain the north side chain and finally elongation of the south side chain was achieved with an isoprene unit. The synthesis of (+)-thiersindole C has corroborated the absolute configuration for the natural product (-)-thiersindole C. The synthesized (+)-thiersindole C showed antitumor activity against a number of human tumor cell lines with an IC₅₀ in the range of 10^-5 M.

Key words

indole diterpene alkaloids - thiersindole C - ent-halimic acid

Full Text

References

References and Notes

<A NAME="RD05207ST-1A">1a</A> Smith AB. Davulku AH. Kürti L. Org. Lett. 2006, 8: 1672

<A NAME="RD05207ST-1B">1b</A> Smith AB. Davulku AH. Kürti L. Org. Lett. 2006, 8: 1668

<A NAME="RD05207ST-1C">1c</A> Smith AB. Cui H. Helv. Chim. Acta 2003, 86: 3908

<A NAME="RD05207ST-2">2</A> Fueki S. Tokiwano T. Toshima H. Oikawa H. Org. Lett. 2004, 6: 2697

<A NAME="RD05207ST-3">3</A> Li C. Gloer JB. Wicklow DT. J. Nat. Prod. 2003, 66: 1232

<A NAME="RD05207ST-4">4</A> Li C. Gloer JB. Wicklow DT. Dowd PF. Org. Lett. 2002, 4: 3095

<A NAME="RD05207ST-5">5</A> Urones JG. Pascual Teresa J. Marcos IS. Diez D. Garrido NM. Alfayate R. Phytochemistry 1987, 26: 1077

<A NAME="RD05207ST-6A">6a</A> Marcos IS. Pedrero AB. Sexmero MJ. Díez D. Basabe P. Hernández FA. Urones JG. Tetrahedron Lett. 2003, 44: 369

<A NAME="RD05207ST-6B">6b</A> Marcos IS. González JL. Sexmero MJ. Díez D. Basabe P. Williams DJ. Simmonds MSJ. Urones JG. Tetrahedron Lett. 2000, 41: 2553

<A NAME="RD05207ST-6C">6c</A> Marcos IS. Pedrero AB. Sexmero MJ. Díez D. García N. Escola MA. Basabe P. Conde A. Moro RF. Urones JG. Synthesis 2005, 3301

<A NAME="RD05207ST-7">7</A> Marcos IS. García N. Sexmero MJ. Basabe P. Díez D. Urones JG. Tetrahedron 2005, 61: 11672

<A NAME="RD05207ST-8">8</A> Marcos IS. Hernández FA. Sexmero MJ. Díez D. Basabe P. Pedrero AB. García N. Urones JG. Tetrahedron 2003, 60: 685

<A NAME="RD05207ST-9">9</A> Marcos IS. Hernández FA. Sexmero MJ. Díez D. Basabe P. García N. Pedrero AB. Sanz F. Urones JG. Tetrahedron Lett. 2002, 43: 1245

<A NAME="RD05207ST-10">10</A> Marcos IS. Pedrero AB. Sexmero MJ. Diez D. Basabe P. García N. Moro RF. Broughton HB. Mollinedo F. Urones JG. J. Org. Chem. 2003, 68: 7496

<A NAME="RD05207ST-11">11</A> Oliver SF. Högenauer K. Simic O. Antonello A. Smith MD. Ley SV. Angew. Chem. Int. Ed. 2003, 42: 5996

<A NAME="RD05207ST-12A">12a</A> Demir AS. Jeganathan A. Synthesis 1992, 235

<A NAME="RD05207ST-12B">12b</A> Sing TKM. Zhu XY. Yeung YY. Chem. Eur. J. 2003, 9: 5489

<A NAME="RD05207ST-12C">12c</A> Sing TKM. Yeung YY. Chem. Eur. J. 2006, 12: 8367

<A NAME="RD05207ST-12D">12d</A> Sing TKM. Yeung YY. Angew. Chem. Int. Ed. 2005, 44: 7981

<A NAME="RD05207ST-13">13</A> Tsuda M. Hatakeyama A. Kobayashi J. J. Chem. Soc., Perkin Trans. 1 1998, 149

<A NAME="RD05207ST-14A">14a</A> Bull JR. Sickle ES. J. Chem. Soc., Perkin Trans. 1 2000, 4476

<A NAME="RD05207ST-14B">14b</A> Paquette LA. Reagents for Organic Synthesis Vol. 6: John Wiley & Sons; New York: 1995. p.4401

<A NAME="RD05207ST-14C">14c</A> Kawabata T. Grieco PA. Sham H.-L. Kim H. Jaw J. Tu S. J. Org. Chem. 1987, 52: 3346

<A NAME="RD05207ST-15">15</A> Marcos IS. Martínez B. Sexmero MJ. Díez D. Basabe P. Urones JG. Synthesis 2006, 3865

<A NAME="RD05207ST-16A">16a</A> Rogers CU. Corson BB. Org. Synth., Coll. Vol. 4 Wiley; New York: 1967. p.884

<A NAME="RD05207ST-16B">16b</A> Trudell ML. Fukada N. Cook JM. J. Org. Chem. 1987, 52: 4293

<A NAME="RD05207ST-16C">16c</A> Robinson B.; The Fischer Indole Synthesis; Wiley-Interscience: New York, 1982

Numbering for compound 4 agrees with that for the thiersindole C skeleton.

Crystal data for 4: C₂₇H₃₅NO₄, monoclinic, space group P2₁ (no 4), a = 7.4100 (15) Å, b = 10.169 (2) Å, c = 16.045 (3) Å, α = γ = 90°, β = 97.11 (3)°, V = 1199.7 (4) Å³, Z = 2, D_c = 1.211 Mg/m³, µ(Cu - K_α) = 0.640 mm^-1, F(000) = 472. The number of reflections collected was 1963, of which 937 were considered to be observed with I > 2σI. The structure was determined by direct methods using the SHELXTL^TM suite of programs. Hydrogen atoms were placed in calculated positions. Full-matrix least squares refinement based on F² with anisotropic thermal parameters for the non-hydrogen atoms led to agreement factors, R₁ = 0.0721 and ωR₂ = 0.1823. Crystallographic data (excluding structure factors) for the structure reported in this paper has been deposited at the Cambridge Crystallographic Data Centre as supplementary material no. CCDC-628164.

<A NAME="RD05207ST-18A">18a</A> Liu HJ. Shia K.-S. Tetrahedron 1998, 54: 13449

<A NAME="RD05207ST-18B">18b</A> Levine SJ. J. Am. Chem. Soc. 1958, 80: 6150

<A NAME="RD05207ST-18C">18c</A> Wittig G. Schlosser M. Chem. Ber. 1961, 94: 1383

<A NAME="RD05207ST-18D">18d</A> Wittig G. Böll W. Krück K.-H. Chem. Ber. 1962, 95: 2514

<A NAME="RD05207ST-18E">18e</A> Wittig G. Angew. Chem. 1956, 68: 505

<A NAME="RD05207ST-18F">18f</A> Marcos IS. Pedrero AB. Sexmero MJ. Díez D. Basabe P. Hernández FA. Broughton HB. Urones JG. Synlett 2002, 105

<A NAME="RD05207ST-19">19</A> Makita N. Hoshino Y. Yamamoto H. Angew. Chem. Int. Ed. 2003, 42: 941

(+)-Thiersindole C(37): [α]_D ²² +54.0 (c = 0.20, CH₂Cl₂). IR (film): 3411, 3056, 2927, 1457, 1375, 1261, 1094, 1046, 1012, 995, 740 cm^-1. ¹H NMR (400 MHz, CDCl₃): δ = 7.89 (br s, 1 H, H-1), 7.60 (d, J = 7.9 Hz, 1 H, H-5), 7.32 (d, J = 8.1 Hz, 1 H, H-8), 7.16 (ddd, J = 1.1, 7.2, 8.1 Hz, 1 H, H-7), 7.10 (ddd, J = 1.1, 7.2, 7.9 Hz, 1 H, H-6), 7.05 (s, 1 H, H-2), 5.10 (br t, J = 6.0 Hz, 1 H, H-23), 3.82 (dd, J = 3.7, 11.1 Hz, 1 H, H-17), 2.92 (d, J = 15.8 Hz, 1 H, H_A-10), 2.84 (d, J = 15.8 Hz, 1 H, H_B-10), 2.37 (m, 1 H, H_A-14), 2.25 (m, 1 H, H_B-14), 2.02 (m, 1 H, H_A-19), 2.00 (m, 1 H, H_A-22), 1.73 (m, 2 H, H_B-19, H_B-22), 1.71 (m, 1 H, H-12), 1.70 (m, 1 H, H_A-18), 1.68 (s, 3 H, Me-26), 1.60 (m, 1 H, H_A-21), 1.55 (s, 3 H, Me-25), 1.49 (m, 1 H, H_A-13), 1.39 (m, 1 H, H_B-13), 1.36 (m, 1 H, H_B-21), 1.03 (s, 3 H, Me-27), 0.98 (s, 3 H, Me-29), 0.86 (d, J = 6.8 Hz, 3 H, Me-28). ¹³C NMR (100 MHz, CDCl₃): δ = 121.4 (C-2), 113.1 (C-3), 128.9 (C-4), 118.7 (C-5), 119.1 (C-6), 121.6 (C-7), 110.8 (C-8), 135.4 (C-9), 31.2 (C-10), 42.1 (C-11), 33.3 (C-12), 27.2 (C-13), 24.8 (C-14), 134.7 (C-15), 43.1 (C-16), 80.0 (C-17), 27.5 (C-18), 24.9 (C-19), 135.0 (C-20), 35.6 (C-21), 23.1 (C-22), 124.8 (C-23), 131.1 (C-24), 25.6 (C-25), 17.7 (C-26), 21.7 (C-27), 16.7 (C-28), 20.4 (C-29). HRMS (ESI): m/z [M⁺ + Na] calcd for C₂₈H₃₉NONa: 428.2924; found: 428.2928.

The in vitro antitumor activity for compound 37, (+)-thiersindole C, was determined by measurement of its cytostatic and cytotoxic properties in human tumor cell lines by the XTT assay, in which the metabolic activity of viable cells was assessed. Cells were incubated in RPMI-1640 (HL-60) or DMEM (HeLa, A549, HT-29) culture medium containing 10% fetal calf serum, in the absence and in the presence of the indicated compound at a concentration range of 10^-4 to 10^-8 M in 96-well plates, and following a 72-h incubation at 37 °C in a humidified atmosphere of air-CO₂ (19:1) the XTT assay was performed. Measurements were done in triplicate, and the IC₅₀ value, defined as the drug concentration required to cause 50% inhibition in the cellular proliferation with respect to the untreated controls, were determined. Values shown are means ±SE of four independent determinations.²²

<A NAME="RD05207ST-22A">22a</A> TePaske MR. Gloer JB. Wicklow DT. Dowd PF. Tetrahedron Lett. 1989, 30: 5965

<A NAME="RD05207ST-22B">22b</A> TePaske MR. Gloer JB. Wicklow DT. Dowd PF. J. Org. Chem. 1989, 54: 4743